Loading
A phase 1/2 trial of Pembrolizumab in head and neck squamous cell carcinoma, run by Psivac Ltd, now recruiting.
Ixovex-1 Single Agent and Combination Therapy is a phase 1/2 interventional study registered as NCT06549946 by Psivac Ltd, with 18 participants planned, started 2024-12-17 and due to reach its primary completion in 2027-01-30. Interventions recorded: Ixovex-1 and Pembrolizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/